A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors

INTRODUCTION: Trastuzumab is effective in human epidermal growth factor receptor 2 (HER2)-over-expressing breast and gastric cancers. However, patients may develop resistance through downstream signaling via the phosphatidylinositol 3-kinase (PI3K)/AKT pathway. This phase 1 trial was conducted to de...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Główni autorzy: Hudis, Clifford, Swanton, Charles, Janjigian, Yelena Y, Lee, Ray, Sutherland, Stephanie, Lehman, Robert, Chandarlapaty, Sarat, Hamilton, Nicola, Gajria, Devika, Knowles, James, Shah, Jigna, Shannon, Keith, Tetteh, Ernestina, Sullivan, Daniel M, Moreno, Carolina, Yan, Li, Han, Hyo Sook
Format: Artigo
Język:Inglês
Wydane: BioMed Central 2013
Hasła przedmiotowe:
Research Article
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3979046/
https://ncbi.nlm.nih.gov/pubmed/24252402
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/bcr3577
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy